Navigation Links
DioGenix' MSPrecise Identifies Early-Stage Patients with Multiple Sclerosis
Date:11/8/2012

GAITHERSBURG, Md., Nov. 8, 2012 /PRNewswire/ -- DioGenix, Inc., a company developing molecular diagnostics for the early diagnosis and monitoring of immune-mediated neurological diseases, today announced its lead product MSPrecise™ outperformed the specificity of the current standard of care for cerebral spinal fluid (CSF) analysis in patients suspected of having multiple sclerosis (MS) by almost two to one with no loss of sensitivity. MSPrecise is a proprietary next-generation sequencing assay that analyzes changes in key genes involved in the adaptive immune system of patients being evaluated for MS. The results of this clinical study are consistent with two prior DioGenix studies, all of which compared MSPrecise results both to published performance data for the oligoclonal banding test and experimental controls.

Patients that present with clinical symptoms and evidence of inflammation and damage to the myelin sheath that surrounds and protects nerve fibers in the CNS undergo a battery of tests in a diagnostic process that can take months to years to complete. The diagnostic standard of care for MS includes CSF analysis using the oligoclonal banding test, which detects immunoglobin G proteins that indicate an immune response within the CNS. Because the oligoclonal banding test yields a high rate of false positive results, confident diagnosis also requires a comprehensive set of clinical tests including magnetic resonance imaging and, in certain cases, visual evoked potentials. Due to the variability of symptoms between patients and the lack of a definitive test, it has been estimated that the misdiagnosis rate for MS is higher than any other immune-mediated neurological disease.

"The results of our most recent study continue to support our belief that MSPrecise will be an important new tool in the management of patients suffering with MS. We have clearly demonstrated, in a series of clinical studies, the pow
'/>"/>

SOURCE DioGenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. From lectures to explosives detection: Laser pointer identifies dangerous chemicals in real-time
2. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
3. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
4. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
5. Multimodal Treatment of Peritoneal Metastases Offers Hope for Many Patients With Colorectal Cancer
6. Stem Cells Bring New Hope for Parry-Romberg Syndrome Patients
7. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
8. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
9. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
10. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
11. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... GEA's Panther™ NS3006L is a ... fully-equipped laboratory unit that is designed for continuous operation ... plants. The Panther™ NS3006L achieves the same results as ... easy installation with simple operation, quick maintenance and is ... used in many different industries, such as food, dairy, ...
(Date:6/2/2015)... June 2, 2015 TapImmune, Inc. (OTCQB: TPIV), ... investors have reached an agreement whereby the institutional investors ... warrants to provide the Company up to $4.93M in ... S-1 registration statement. Under the restructured terms and subject ... additional warrants which could result in a larger influx ...
(Date:6/2/2015)... 02, 2015 Global Stem Cells Group ... for Bioquark, Inc.’s biologic products for the regeneration and repair ... in Global Stem Cells Group’s ambitious expansion plans in Latin ... for access to regenerative medicine and stem cell therapies. ... of biologics that have the ability to alter the regulatory ...
(Date:6/2/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/2b7734/molecular ) has ... Global Market Size, Strategy and Forecasts - 2015 to ... Diagnostics - Global Market Size, Strategy and Forecasts - ... can use. Hundreds of pages of information including a ... Payment Schedules to help understand test pricing in detail. ...
Breaking Biology Technology:GEA Announces the Panther™ NS3006L, a Self-Contained, Fully-Equipped Laboratory Homogenizer Well Suited for Pilot Plants 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 3
... to Membership , , , COLD SPRING HARBOR, ... year agreement with Amerinet Inc. to offer the AccuVein AV300, ... members. The AccuVein AV300 projects a pattern of light ... healthcare professional locate veins for blood draw (venipuncture), IV starts ...
... , NEW YORK, June 8 Keryx Biopharmaceuticals, Inc. ... the Phase 2 study of Zerenex (ferric citrate) for ... in patients with end-stage renal disease (ESRD) on thrice ... clinical trial, which enrolled 55 patients. The primary objective ...
... , DUROS(R) continuous delivery of exenatide produces impressive reductions ... 28-day treatment , , NEW ORLEANS, June 8 ... first clinical study of ITCA 650 (DUROS(R) continuous delivery ... as a late-breaker at the Annual Conference of the ...
Cached Biology Technology:AccuVein Inks National Three-Year Group Purchasing Deal With Amerinet 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients 3Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients 4Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients 5Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 2Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 3Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 4
(Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
(Date:5/6/2015)... AVIV, Israel , May 6, 2015 ... world,s most established helmet producer, announced today that they ... Smart Helmet, the world,s first bio-sensing cycling helmet and ... be released in two new colors in order to ... for the product. In addition, LifeBEAM and Lazer announced ...
(Date:4/27/2015)... 2015 Profile Solutions, Inc. (OTC: PSIQ), a ... is pleased to announce that Dr Gerry Bedore ... member of its scientific advisory board. ... thought leader in technology-enhanced learning models. He was a ... published studies and books focused on online student success ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Finding cures for hearing loss, breast cancer and childhood ... for tuberculosis are goals of the first recipients of ... Collaborative Research Fund. The fund, a $3 million initiative ... supports collaboration among researchers at Rice University, Texas Children,s ...
... three undergraduates set off on an expedition in 1965 to ... realise that they were establishing the groundwork for a study ... led by the University of York has repeated the survey ... moved uphill by about 67 metres over the intervening years ...
... COLUMBIA, Mo. When it is head versus heart, ... organ to develop and is critical in supplying blood ... known about the complex processes that regulate the heartbeat. ... has identified certain proteins within the heart muscle that ...
Cached Biology News:Texas Medical Center researchers win collaborative grants 2Texas Medical Center researchers win collaborative grants 3Texas Medical Center researchers win collaborative grants 4The global impact of climate change on biodiversity 2Researchers examine developing hearts in chickens to find solutions for human heart abnormalities 2
... Rabbit polyclonal to MSY2/YBOX2 ( ... Antigen: Synthetic ... to the C-terminus of Human MSY2/YBOX2. ... is proprietary) (Peptide ...
Request Info...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Biology Products: